Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Novartis AG NVS
$103.05
-$0.37 (-0.36%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
218394014701.00000000
-
week52high
105.56
-
week52low
74.09
-
Revenue
51828000000
-
P/E TTM
31
-
Beta
0.46221300
-
EPS
3.29000000
-
Last Dividend
3.50000000
-
Next Earnings Date
25 апр 2023 г. в 04:00
Описание компании
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Outperform | 09 мая 2022 г. |
| Exane BNP Paribas | Neutral | Outperform | 06 дек 2021 г. |
| Bryan Garnier | Neutral | Buy | 03 дек 2021 г. |
| Deutsche Bank | Sell | Hold | 20 сент 2021 г. |
| Argus Research | Hold | Buy | 10 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | 6503191 | 465677 | 30 сент 2022 г. |
| GABELLI FUNDS LLC | 89500 | 0 | 30 сент 2022 г. |
| NEW YORK STATE COMMON RETIREMENT FUND | 79327 | 0 | 30 сент 2022 г. |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 14820 | -2981 | 30 сент 2022 г. |
| Privium Fund Management B.V. | 11250 | 11250 | 30 сент 2022 г. |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 308000 | -237900 | 31 мар 2022 г. |
| Royal Fund Management, LLC | 29362 | -1706 | 31 мар 2022 г. |
| Davy Global Fund Management Ltd | 16947 | 2300 | 31 мар 2022 г. |
| CAPITAL FUND MANAGEMENT S.A. | 11996 | 11996 | 12 февр 2021 г. |
| SPHERA FUNDS MANAGEMENT LTD. | 549000 | 0 | 31 дек 2020 г. |
Новостная лента
What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
10 мая 2023 г. в 13:41
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
10 мая 2023 г. в 11:26
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Here's Why Novartis (NVS) is a Strong Value Stock
Zacks Investment Research
09 мая 2023 г. в 11:27
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis ‘focusing on high-end, innovative medicines,' CEO says
Yahoo Finance
09 мая 2023 г. в 10:24
Novartis CEO Vas Narasimhan joins Yahoo Finance Live anchors to discuss company earnings, focusing efforts on fighting cancer, consumer health, and cutting roughly 10% of the global healthcare company's experimental drug pipeline.
5 Dividend Growth Stocks to Buy for Safe Returns
Zacks Investment Research
08 мая 2023 г. в 09:54
PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.